All posts in News

The company’s annual retreat took place this year in December in Espacio Mood in Barcelona. A few internal training pills were provided by some members of SYNAPSE centred on IMI-2, the transition to the new IMI portal, and the key aspects affecting new IMI projects and proposals next year.

The meeting followed with specific corporate strategy-focused sessions addressing internal operating procedures and the new challenges for 2017. Aspects such as quality, proficiency and commitment were brought to the table by all members of the team through open and lively discussions. The new year will come with new projects and exciting challenges and we are all ready to face them.

Let’s go!

synapse_retreat-2016

Synapse is the project manager for the ROADMAP project (Real world Outcomes across the Alzheimer’s Disease (AD) spectrum for better care: Multi-modal data Access Platform), kicked-off on November 16-17, 2016 in Barcelona, which will deliver a series of scalable, transferable data integration methods and tools for patient outcomes, developed and tested through pilot projects, which will provide the foundation for a Europe-wide Real World Evidence (RWE) platform on AD.

Successfully delivering therapies to people with AD will also depend on building a sustainable global payer strategy to address challenges around drug access to markets. This will be dependent on the integration of RWE in health care systems to support approval as well as HTA/payer evidence. The development of a sustainable global payers strategy is one of ROADMAP’s objectives.

As the result of an ageing population, rising costs and more specialised treatments, Europe is now facing an acute healthcare challenge. In no area is this more apparent than in AD and dementia. The European Union, with the world’s most diverse and sophisticated health care systems, is uniquely placed to develop and exploit technologies to support RWE; addressing operational issues of data access, integration and security, alongside hypothesis testing, ELSI, health economic and budget impact, at a level of detail and complexity not possible elsewhere.

ROADMAP will identify RWE to better inform regulators on matters of efficacy and safety, providers on cost effectiveness, industry on pricing and manufacturing and scientists on mechanisms and pathways, to accelerate decision-making on re-purposing current treatments and developing new treatments.

ROADMAP brings together world-leading experts from 22 partner organisations to apply cutting-edge technology to a body of data of unprecedented depth and breadth, drawn from 6 EU Member States (Denmark, France, Netherlands, Spain, Sweden, UK), involving 75 national databases and clinical registries, more than 40 cohorts, several studies and 5 dementia-relevant trials, providing a unique opportunity for RWE in general, as well as in the dementia context.

The 2-year project is led by Novartis and coordinated by the University of Oxford. Synapse leads the Project Management work package and is involved in the design and implementation of the communication and patient/healthcare provider engagement strategy within WP7.

ROADMAP is mainly sponsored by the European Union’s Horizon 2020 research and innovation programme and the European pharmaceutical industry (via EFPIA) under the auspices of the Innovative Medicines Initiative 2 Joint Undertaking (www.imi.europa.eu).

For more information, check out http://www.roadmap-alzheimer.org/.

Synapse is the amypad_logoproject manager for the AMYPAD project (Amyloid imaging to prevent Alzheimer’s disease), kicked-off on October 5-6, 2016 in London, which will investigate the value of β-amyloid using positron emission tomography (PET) imaging as a diagnostic and therapeutic marker for Alzheimer’s dementia.

Beta-amyloid (β-amyloid) deposition in the brain is one of the neuropathological hallmarks on the path towards development of Alzheimer’s disease (AD). The recent advent of commercially available β-amyloid PET tracers has opened up new potential for the visualisation of brain β-amyloid in vivo. It may improve an early diagnosis of AD, and, when recognised in a pre-symptomatic population, even provide an opportunity for secondary prevention of AD. However, the full value of this relatively novel technology and its optimal position in the diagnostic workup of patients is not yet fully understood.

AMYPAD will determine in a real-life clinical setting for whom diagnostic β-amyloid imaging is appropriate, when this is best performed and how the resulting information is influencing diagnostic certainty, patient management and ultimately decision trees and cost-effectiveness of dementia care.

The AMYPAD consortium (15 public and private organisations formed by academic institutions, pharmaceutical companies, SMEs and patient organisations) will address the above goals in close collaboration with IMI-JU project EPAD (European prevention of Alzheimer’s dementia | www.ep-ad.org), a major global initiative, also managed by Synapse, to create a novel environment for testing new treatments for the prevention of Alzheimer’s dementia.

The project is led by GE Healthcare Life Sciences and coordinated by VU University Medical Center, Amsterdam. Synapse is member of the Executive Committee, leads the Project Management work package, and is involved in the design and implementation of dissemination plans and communication strategy within WP6 (Ethics, communication and dissemination) activities.

AMYPAD is mainly sponsored by the European Union’s Horizon 2020 research and innovation programme and the European pharmaceutical industry (via EFPIA) under the auspices of the Innovative Medicines Initiative 2 Joint Undertaking (www.imi.europa.eu).

For more information, contact info@amypad.eu, check out www.amypad.eu or follow @IMI_AMYPAD on Twitter.

The Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences (NDORMS, University of Oxford) launched the 1st edition of Real World Data Epidemiology Summer School, sponsored by Synapse Research Management Partners and IMI-EMIF. The course was focused on the review of the existing sources and the basic introductory concepts of pharmacoepidemiology and medical device epidemiology using observational, routinely collected or registry-based data. The Summer School took place on 11th-15th of July in Oxford.

The course gathered a large number of participants, pharmacists, clinicians, registry staff, statisticians, epidemiologists, and related MSc/PhD students from the UK, Spain, Sweden, Italy, Hong Kong and other countries.

Renowned experts from academy and industry shared with the students their knowledge, views and potential solutions applied to the use of big health data.

During the course, the students were actively encouraged to participate in the interactive sessions as part of the training. These sessions allowed to address skills of study designs for the use of routinely collected healthcare data and understand the relevant issues using electronic health records: misclassification and potential bias, data management and interaction with industry and regulators.

The EPAD project, one of the major studies in Europe to find interventions that prevent the onset of Alzheimer’s dementia, has recruited its first participant. Julie Duffus, from Edinburgh (Scotland), is the first person to take part in the project.

Participants will have regular health checks including blood tests and brain scans. Researchers will also track their thinking skills over time using tests of mental agility. Afterwards, they will be invited to take part in clinical trials aimed at testing interventions that could delay, or even prevent, the onset of dementia.

According to Carlos Diaz, project manager of EPAD and CEO of SYNAPSE Research Management Partners: “The first patient in is one of the key and most exciting milestones in EPAD, the first step towards building the Longitudinal Cohort Study that will help us better understand early signs of Alzheimer’s disease. We are proud at SYNAPSE of our role as Algorithm Running Committee, which plays a critical part in the selection of all 6,000 volunteers to be involved in the EPAD project from across Europe.”

The 5-year, 36-partner, 64-million euro, Europe-wide initiative aims to improve understanding of the early stages of Alzheimer’s disease and how it leads to dementia. EPAD is mainly sponsored by the European Commission and the European pharmaceutical industry (via EFPIA) under the auspices of the Innovative Medicines Initiative Joint Undertaking (IMI JU). For more information: www.ep-ad.org.

SYNAPSE supports the organization of the 1st European Conference on Translational Bioinformatics (ECTB 2016) that will happen at the University of Copenhagen on April 26-27 2016.

The conference, organized by the “Novo Nordisk Foundation Center for Protein Research” at the University of Copenhagen and supported by the Horizon 2020 MedBioinformatics project, will address among others the following topics:

  • Big biomedical data approaches converting health data to clinically relevant information
  • Health data capture and curation
  • Phenotypic data and metadata
  • Precision medicine
  • Data integration and analytics combining molecular biomarker data with clinical data
  • Secure private cloud technology for person-sensitive data
  • The future of sustainable healthcare models
  • Ethics and data protection  in the context of medical informatics

MedBioinformatics plans to support the organization of three conferences (one per year) during its life, happening in Copenhagen, London and Barcelona respectively, with the objective of consolidating the event (the first of its kind in Europe) beyond the project life as a reference framework for meeting, discussing and presenting advancements and challenges around the bioinformatics area in Europe.

The conference will bring together world-leading scientists in the area and aims to give the participants a unique experience and a forum for discussing fresh scientific results in the translational domain.

For more information about the conference and registration, please visit: http://www.translational.bi2016.eu/

banner_superior_Hresolution

SYNAPSE is proud to co-organise the “Harmonized Safety Monitoring of Immunization in Pregnancy International Consensus Conference” that will happen at the NIH Campus (Bethesda, MD, USA) on March 29-30 2016.

The conference, supported by the Bill & Melinda Gates Foundation and the GAIA project, will aim to highlight progress in harmonizing safety monitoring of immunization in pregnancy and to develop consensus recommendations for a globally concerted approach.

Specifically, the conference will allow critical face-to-face review of GAIA outputs (first set of 10 case definitions, guidance for data collection, and data collection matrix) with regulators, public health agencies, manufacturers and academia in the context of current achievements and challenges in the evolving field of immunization in pregnancy. Discussions related to the GAIA project will focus on acceptability and usefulness of the outcomes in Low and Middle-Income Countries (LMIC) and on promoting their recommendation and future implementation by stakeholder organizations.

For more information about the conference, please visit: http://immunization-in-pregnancy-2016.iabs.org/index.html

 

Banner_ICC_venue_20160113
The company’s annual retreat took place this year in December in Artchimboldi in Barcelona. During two full days, SYNAPSE’s team was fully immersed on internal training and discussions around SYNAPSE.

Training was focused on in-depth knowledge of overall impact and sustainability of research results, stakeholder management, analysis of best practices when it comes to the management of complex distributed project, and approaches for improving legal, financial and communication efforts.

The corporate strategy sessions addressed aspects such as quality, proficiency and corporate communications as key pillars, and counted with the contributions of all members of the team to the lively discussions. 2016 comes full of interesting projects and challenges that will require commitment and enthusiasm.

We are all ready here.

IMG_1337

The European Prevention of Alzheimer’s Dementia Consortium (EPAD), a project co-funded by the Innovative Medicines Initiative (IMI) and the European Federation of Pharmaceutical Industries and Associations (EFPIA), announces today the official launch of www.ep-ad.org. The EPAD website is devoted to inform different audiences including the scientific community, companies, people with dementia, families and carers, Alzheimer associations and the general public, about the project’s existence, its progress and its achievements.

ScreenClip

SYNAPSE will attend the eHealth Week 2015 that will be held in Riga (Latvia) on 11-13 May 2015. Ángel Honrado, SYNAPSE’s Head of the Projects and Services Unit, will be in the event as part of the delegation of the FP7 SEMCARE project, which will be presenting a demonstration of the platform’s prototype in booth 705. As leader of the Business Modelling and Dissemination activities in SEMCARE, SYNAPSE’s role will focus on collecting feedback from the different stakeholders attending the event, which will be key for identifying and analysing their needs and use their inputs for the business roadmap that is currently under development.

himsseu_ehealth_week_1200x357_v9

The eHealth Week 2015 comprises two main events: the High Level eHealth Conference and the WoHIT (World of Health IT Conference & Exhibition) organised. Over 2,000 international delegates and 75 exhibitors are expected to attend the event, which count with global decision makers from public and private healthcare sectors, clinicians, hospital and IT managers, among others attendees. Besides the two main events, all eHealth Week participants can attend a range of sessions and activities including mHealth Summit EuropeEU SME eHealth Competition, an onsite Matchmaking Event and a state of the art exhibition including country pavilions from all over the world.

The programme of the whole event is available here

Prev123Next